Abstract:9040 Background: Imatinib generated remarkable clinical response in melanomas harboring c-kit mutation. However, melanoma resistance to imatinib develops rather quickly in most of the patients. It has been shown that gene mutations, translocations, deletions, amplifications, and epigenetic changes are involved in the process of secondary imatinib-resistance in GI stromal tumor. But imatinib resistance in melanoma has not been well evaluated. Methods: The level of miRNAs expression was initially discovered through miRNA profiling using pretreatment and post treatment imatinib resistant melanoma tissues, and then confirmed by quantitative PCR. Scratch wound and in vitro invasion assays were performed to evaluate cell migration and invasion. Luciferase reporter assays, immunoblots, and immunohistochemistry analyses were conducted to examine the association between miR-18a and their targets in imatinib-resistant cell and specimens. Results: miR-18a was dramatically down-regulated in secondary imatinib-resistant melanoma tissues. Reintroduction of miR-18a led to imatinib-resistant cells become sensitive to imatinib treatment. Cell cycle and apoptosis analysis indicated that miR-18a overexpression in combination with imatinib treatment resulted in a decrease of cell numbers of S-phase and an increase of apoptotic cells, respectively. Wound healing assay and in vitro invasion assay indicated enforced expression of miR-18a, as well as imatinib treatment dampened the capacity of melanoma cell migration and metastasis. CCND2 and Notch2 were validated as bona fide effectors of miR-18a in melanoma cells. Furthermore, rescued assay was performed to probe the interaction among miR-18a, CCND2/Notch2, and phenotypic alterations, which demonstrated that the sensitivity of imatinib therapy on imatinib-resistant cell line was improved through miR-18a mediated regulation of CCND2/Notch2. Conclusions: Targeting of miR-18a is sufficient to enhance the therapeutic effect of imatinib on melanoma treatment, suggesting that restoration of miR-18a may be a promising strategy for the prevention of melanoma patients from developing secondary resistance.

Anril Lncrna Triggers Efficient Therapeutic Efficacy by Reprogramming the Aberrant Ink4-Hub in Melanoma

Inhibition of AURKB, regulated by pseudogene <i>MTND4P12</i>, confers synthetic lethality to PARP inhibition in skin cutaneous melanoma

A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib

Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling

Codelivery of afuresertib and celecoxib by IL4RPep-1-targeting nanoparticles for effective treatment against melanoma

Kinetic Inference Resolves Epigenetic Mechanism of Drug Resistance in Melanoma

Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference

Elevated LINC01550 induces the apoptosis and cell cycle arrest of melanoma

Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma Via Recruiting EZH2

Abstract 2469: PROTAC mediated NR4A1 degradation as a novel strategy for cancer immunotherapy

Effect of Restoration of Microrna-18A on Improvement of Imatinib Therapy on Secondary Imatinib-Resistance Metastatic Melanoma.

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma

Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.

Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers

Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells

Oncogenic LINC00698 Suppresses Apoptosis of Melanoma Stem Cells to Promote Tumorigenesis Via LINC00698-miR-3132-TCF7/hnRNPM Axis

Exploiting in Situ Antigen Generation and Immune Modulation to Enhance Chemotherapy Response in Advanced Melanoma: A Combination Nanomedicine Approach.

Genetic Aberrations in the CDK4 Pathway and Association with Innate Resistance to PD-1 Blockade in Acral Melanoma.

Targeted therapeutic strategies for melanoma